Neoadjuvant nivolumab plus bevacizumab therapy improves the prognosis of triple-negative breast cancer in humanized mouse models

CONCLUSION: The preclinical study has demonstrated the therapeutic efficacy and mechanism of neoadjuvant combination therapy (nivolumab plus bevacizumab) in treating early TNBC.PMID:38289410 | DOI:10.1007/s12282-024-01543-z
Source: Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research